Investor Relations

News Releases

 
News Releases
  Date Title View
Oct 25, 2017
Completed Enrollment in CINGAL Phase III Clinical Trial;Advancement of Regenerative Medicine Pipeline;MONOVISC Revenue Increased 50% Year-over-Year BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic med...
Oct 25, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the completion of enrollment in its second pivotal Phase III trial evaluat...
Oct 23, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Thomas M. Finnerty as its Chief Human Resources Officer...
Oct 16, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that regulatory authorities in Australia granted approval to MONOVISC®...
Oct 11, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017, at 9:00 a...
Aug 28, 2017
Deep international expertise to drive the Company's global expansion BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, ...
Aug 7, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the publication of data demonstrating that HYALOFAST®, a bio...
Jul 27, 2017
Track Record of Successful Product Launch and Global Commercial Expansion BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"...
Jul 26, 2017
MONOVISC U.S. End-User Sales Exceeded $100 Million at an Accelerated Pace CINGAL Phase III Clinical Trial Achieved Rapid Advancements BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company...
Jul 24, 2017
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that regulatory authorities in India granted approval to MONOVISC®, ...

= add release to Briefcase